Taisho Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company. Taisho Company, along with its subsidiaries and associated companies, operates in two business segment. The Self Medication segment is engaged in the research, development, manufacture and sale of self-medication pharmaceuticals, quasi drugs and food products. This segment is also involved in the provision of insurance services, logistics services, printing services, as well as real estate leasing, management and operation services. The Prescribed Medication segment is engaged in the development, manufacture and sale of prescribed pharmaceuticals. Taisho Company has 23 subsidiaries and three associated companies. The Company acquired 97.97% stake in PT Bristol-Myers Squibb Indonesia Tbk. on October 31, 2009.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

POZEN, Inc. was founded in 1996 and is headquartered in Chapel Hill, North Carolina. POZEN, Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has development and commercialization alliances with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers.

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

Peptimmune is pepped up about stopping the immune system when it malfunctions. The research-stage biotechnology company is focused on developing pharmaceuticals that treat medical conditions in which the body essentially attacks itself. Peptimmune conducts research and development programs on potential drug candidates targeting autoimmune and inflammatory ailments such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. The company partners with other pharmaceutical firms in some of its drug development efforts; it also relies on venture capital investors to help fund its research.

Mediatech, Inc. company develops, manufactures, and distributes molecular biology and cell culture reagents used by research labs. Its customers include pharmaceutical companies, government agencies, and academic institutions. Mediatech's products are sold under the cellgro and Insectagro brands, and include cell culture media, reagents, salt solutions, antibiotics, and bioprocess collection containers. The company also provides custom formulation and contract manufacturing services. Its products are sold in the US through its own sales force and through third-party distributors internationally. Mediatech was formed in 1984.

Boiron believes in nature's cures. The company makes homeopathic remedies to combat such maladies as colds, the flu, allergies, and anxiety. Founded in 1911, it is one of the oldest and largest such firms in Europe. It dominates its home market of France and also operates in Africa, Australia, North and South America, and the Middle East through about 20 subsidiaries. Along with homeopathic remedies, Boiron develops personal, animal care, and nutritional products for sale in some markets, including France (but not the US). One of the company's key products is Oscillococcinum six-dose homeopathic flu medicine. Used throughout the world, Oscillo is one of the largest homeopathic flu medicines in the US.

DPT Laboratories will turn a discovered drug into a developed and commercialized drug. The contract manufacturing and development company makes prescription and over-the-counter drugs with an emphasis on semi-solid and liquid formulations including lotions, gels, aerosol foams, nasal sprays, and creams. It works with both conventional and biopharmaceutical compounds and can manufacture small quantities for pilots and clinical trials, and all the way up to commercial production. DPT is a subsidiary of DFB Pharmaceuticals and has manufacturing facilities in Texas and New Jersey.

Halozyme Therapeutics, Inc. company was founded in 1998 and is based in San Diego, California. Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (Matrix) for the endocrinology, oncology, dermatology and drug delivery markets The Company's products are based on the property covering the family of human enzymes known as hyaluronidases. The Company has two marketed products: HYLENEX, a product used as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids, and Cumulase, a product used for in vitro fertilization (IVF). The Company has partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. (Roche), to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets, and with Baxter Healthcare Corporation (Baxter), to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.